Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 260

1.

Indirect effects associated with widespread vaccination of infants with heptavalent pneumococcal conjugate vaccine (PCV7; Prevnar).

Isaacman DJ, Fletcher MA, Fritzell B, Ciuryla V, Schranz J.

Vaccine. 2007 Mar 22;25(13):2420-7. Epub 2006 Sep 18.

PMID:
17049677
2.

Herd immunity and pneumococcal conjugate vaccine: a quantitative model.

Haber M, Barskey A, Baughman W, Barker L, Whitney CG, Shaw KM, Orenstein W, Stephens DS.

Vaccine. 2007 Jul 20;25(29):5390-8. Epub 2007 May 22.

PMID:
17583392
3.

The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.

Isaacman DJ, Strutton DR, Kalpas EA, Horowicz-Mehler N, Stern LS, Casciano R, Ciuryla V.

Clin Ther. 2008 Feb;30(2):341-57. doi: 10.1016/j.clinthera.2008.02.003. Review.

PMID:
18343273
4.

Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.

Lloyd A, Patel N, Scott DA, Runge C, Claes C, Rose M.

Eur J Health Econ. 2008 Feb;9(1):7-15. Epub 2007 Mar 2.

PMID:
17333089
5.

Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2008 Feb 15;57(6):144-8.

6.
7.

Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine.

Muñoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ, Pallares R.

Clin Infect Dis. 2008 Jan 15;46(2):174-82. doi: 10.1086/524660.

PMID:
18171247
8.

Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine.

Hsu K, Pelton S, Karumuri S, Heisey-Grove D, Klein J; Massachusetts Department of Public Health Epidemiologists.

Pediatr Infect Dis J. 2005 Jan;24(1):17-23.

PMID:
15665705
9.

Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: progress towards elimination of a health disparity.

Hennessy TW, Singleton RJ, Bulkow LR, Bruden DL, Hurlburt DA, Parks D, Moore M, Parkinson AJ, Schuchat A, Butler JC.

Vaccine. 2005 Dec 1;23(48-49):5464-73. Epub 2005 Sep 12.

PMID:
16188350
10.

Transmission-dynamic model to capture the indirect effects of infant vaccination with Prevnar (7-valent pneumococcal conjugate vaccine (PCV7)) in older populations.

Snedecor SJ, Strutton DR, Ciuryla V, Schwartz EJ, Botteman MF.

Vaccine. 2009 Jul 23;27(34):4694-703. doi: 10.1016/j.vaccine.2009.05.062. Epub 2009 Jun 9.

PMID:
19520197
11.
12.

Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.

Lacapa R, Bliss SJ, Larzelere-Hinton F, Eagle KJ, McGinty DJ, Parkinson AJ, Santosham M, Craig MJ, O'Brien KL.

Clin Infect Dis. 2008 Aug 15;47(4):476-84. doi: 10.1086/590001.

PMID:
18627249
13.

Has the seven-valent pneumococcal conjugate vaccine had an impact on invasive pneumococcal disease in Western Australia?

Giele C, Moore H, Bayley K, Harrison C, Murphy D, Rooney K, Keil AD, Lehmann D.

Vaccine. 2007 Mar 22;25(13):2379-84. Epub 2006 Sep 18.

PMID:
17064825
14.

[Heptavalent-pneumococcal conjugate vaccine (Prevenar). Differences in effectiveness between populations].

Guevara M, Barricarte A, Pérez B, Arriazu M, García Cenoz M, Castilla J.

An Sist Sanit Navar. 2008 May-Aug;31(2):171-92. Review. Spanish.

15.

Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model.

De Wals P, Black S, Borrow R, Pearce D.

Clin Ther. 2009 Oct;31(10):2152-69. doi: 10.1016/j.clinthera.2009.10.014.

PMID:
19922887
16.

Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups.

Byington CL, Samore MH, Stoddard GJ, Barlow S, Daly J, Korgenski K, Firth S, Glover D, Jensen J, Mason EO, Shutt CK, Pavia AT.

Clin Infect Dis. 2005 Jul 1;41(1):21-9. Epub 2005 May 26.

PMID:
15937758
17.

Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Programme.

Harboe ZB, Valentiner-Branth P, Benfield TL, Christensen JJ, Andersen PH, Howitz M, Krogfelt KA, Lambertsen L, Konradsen HB.

Vaccine. 2010 Mar 19;28(14):2642-7. doi: 10.1016/j.vaccine.2010.01.017. Epub 2010 Jan 20.

PMID:
20096392
18.

Epidemiology of invasive pneumococcal disease among adult patients in barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007.

Ardanuy C, Tubau F, Pallares R, Calatayud L, Domínguez MA, Rolo D, Grau I, Martín R, Liñares J.

Clin Infect Dis. 2009 Jan 1;48(1):57-64. doi: 10.1086/594125.

PMID:
19035779
19.

Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente.

Black S, Shinefield H, Baxter R, Austrian R, Bracken L, Hansen J, Lewis E, Fireman B.

Pediatr Infect Dis J. 2004 Jun;23(6):485-9.

PMID:
15194827
20.

Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members.

Millar EV, Watt JP, Bronsdon MA, Dallas J, Reid R, Santosham M, O'Brien KL.

Clin Infect Dis. 2008 Oct 15;47(8):989-96. doi: 10.1086/591966.

PMID:
18781875

Supplemental Content

Support Center